{"id":12497,"date":"2021-06-24T18:54:23","date_gmt":"2021-06-24T13:24:23","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12497"},"modified":"2022-08-16T10:21:55","modified_gmt":"2022-08-16T04:51:55","slug":"recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","title":{"rendered":"Insilico Medicine raises $255M; Sanofi &#038; Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex &#038; Intellia form CAR-T startup"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4d7525ead6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4d7525ead6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\/#Insilico_Medicine_raises_USD_255_Million_for_AI_drug_discovery\" >Insilico Medicine raises USD 255 Million for AI drug discovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\/#Sanofi_and_Translate_Bio_initiate_Phase_1_clinical_trial_of_mRNA_influenza_vaccine\" >Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\/#Medtronic_gains_expanded_FDA_approval_for_Arctic_Front_cryoablation_catheters\" >Medtronic gains expanded FDA approval for Arctic Front cryoablation catheters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\/#Blackstone_Cellex_and_Intellia_form_USD_250_Million_CAR-T_startup\" >Blackstone, Cellex, and Intellia form USD 250 Million CAR-T startup<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-insilico-medicine-raises-usd-255-million-for-ai-drug-discovery\"><span class=\"ez-toc-section\" id=\"Insilico_Medicine_raises_USD_255_Million_for_AI_drug_discovery\"><\/span><strong>Insilico Medicine raises USD 255 Million for AI drug discovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Insilico Medicine, a Hong Kong-based global leader in end-to-end <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence-in-healthcare\">artificial intelligence<\/a><\/strong> for target discovery, small molecule chemistry, and clinical development, closed a USD 255 Million Series C financing.<\/p>\n\n\n\n<p>Warburg Pincus led the round with participation from present investors Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners. In alliance with the funding, Min Fang, Managing Director at Warburg Pincus, will meet Insilico Medicine\u2019s Board of Directors.<\/p>\n\n\n\n<p>The company intends to utilize the funds to support its current therapeutic programs into human clinical trials, commence multiple new programs for novel and challenging targets, and further develop its <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/artificial-intelligence-2\">AI and drug discovery capabilities<\/a><\/strong>.<\/p>\n\n\n\n<p>Led by Alex Zhavoronkov, Ph.D., founder, and CEO, Insilico Medicine develops <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/medtech-industry-and-artificial-intelligence\">artificial intelligence systems<\/a><\/strong> that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties. The company also creates software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-and-translate-bio-initiate-phase-1-clinical-trial-of-mrna-influenza-vaccine\"><span class=\"ez-toc-section\" id=\"Sanofi_and_Translate_Bio_initiate_Phase_1_clinical_trial_of_mRNA_influenza_vaccine\"><\/span><strong>Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi and Translate Bio have initiated a phase 1 clinical trial of an <strong>mRNA vaccine<\/strong> for seasonal influenza. The commencement of the study puts the partners ahead of Moderna and Pfizer in the race to prove mRNA vaccines are as good or better at stopping flu than current technologies.&nbsp;<\/p>\n\n\n\n<p>The validation of mRNA technology by vaccines against COVID-19 has increased interest in using the approach to protect against seasonal flu. Moderna revealed three flu vaccines in January and schedules to get into the clinic this year. Pfizer has also shown an interest in <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\">mRNA flu vaccines<\/a><\/strong>, while CureVac has been working on the idea for many years with the funding of the Bill &amp; Melinda Gates Foundation.&nbsp;<\/p>\n\n\n\n<p>Sanofi and Translate Bio have superseded their rivals to the clinic, though, hailing the initiation of their study as the first human trial of a seasonal <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\">mRNA flu vaccine candidate<\/a><\/strong>. The study will evaluate the safety and immunogenicity of various doses of two mRNA vaccine formulations designed to protect against A\/H3N2, a strain of influenza-associated with more severe flu seasons.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-gains-expanded-fda-approval-for-arctic-front-cryoablation-catheters\"><span class=\"ez-toc-section\" id=\"Medtronic_gains_expanded_FDA_approval_for_Arctic_Front_cryoablation_catheters\"><\/span><strong>Medtronic gains expanded FDA approval for Arctic Front cryoablation catheters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Medtronic has gained expanded FDA approval for its Arctic Front cardiac cryoablation catheters to be used as a first-line treatment for recurrent <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market\">atrial fibrillation (AFib)<\/a><\/strong>. The company\u2019s entire line of Arctic Front cryoablation catheters is covered in this approval.<\/p>\n\n\n\n<p>As per Medtronic, this is the first time cryoablation has been approved as a first-line treatment for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-heart-failure-ahf-market\">heart rhythm<\/a><\/strong> issues. The expanded approval was based on the STOP AF First trial results, a randomized study that comprised data from 225 patients receiving care at 24 different U.S. facilities. In that analysis, the treatment success rate was much higher for cryoablation patients than patients who underwent antiarrhythmic drug therapy.<\/p>\n\n\n\n<p>Rebeca Seidel, Medtronic\u2019s president of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiac-ablation-devices-market\">cardiac ablation<\/a><\/strong> solutions, said in a prepared statement that Medtronic now has the only ablation catheter approved by the FDA to be used as a first-line treatment in the U.S. to treat AFib. The indication expansion shows how Medtronic continues to lead the way in cardiac ablation solutions for arrhythmia management and meet a market need for an early rhythm control strategy for very progressive disease. In addition, for the millions of Americans who struggle with simple, daily tasks, the expanded indication proffers an alternative treatment option to antiarrhythmic drug therapy.<\/p>\n\n\n\n<p>Patients can now be referred for cryoablation to effectively manage their AFib rather than trying drug therapy first, potentially letting them get back to living their lives without the added <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-anxiety-disorder-gad-market\">anxiety <\/a><\/strong>of progressing AFib symptoms and potential health complications, as said by Oussama Wazni, MD, principal investigator for the STOP AF First trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-blackstone-cellex-and-intellia-form-usd-250-million-car-t-startup\"><span class=\"ez-toc-section\" id=\"Blackstone_Cellex_and_Intellia_form_USD_250_Million_CAR-T_startup\"><\/span><strong>Blackstone, Cellex, and Intellia form USD 250 Million CAR-T startup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics have teamed to develop a <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T therapy<\/a><\/strong> startup. The biotech begins life with USD 250 million from Blackstone, universal CAR-T platforms from Cellex, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/crispr-therapies-pipeline-insight\"><strong>CRISPR\/Cas9 genome editing technology<\/strong><\/a> from Intellia.<\/p>\n\n\n\n<p>GEMoaB, a subsidiary of Cellex, is developing platforms to enhance the therapeutic window of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight\">CAR T-cell therapies<\/a><\/strong> and let them be silenced in less than four hours. Intellia and GEMoaB formed a research collaboration and license agreement last year to evaluate the combination of their genome editing technologies and quickly switchable universal CAR-T platform RevCAR, respectively.&nbsp;<\/p>\n\n\n\n<p>Involving Blackstone positions GEMoaB and Intellia to step up the CAR-T work. The new company will take over GEMoaB and its offices in Germany and set up in Cambridge, Massachusetts.&nbsp;<\/p>\n\n\n\n<p>Led by Andrew Schiermeier, currently a chief operating officer at Intellia, the company will advance a pipeline of cell therapies based on its exclusive license to combine Intellia\u2019s CRISPR\/Cas9 allogeneic platform with GEMoaB\u2019s two switchable, universal <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-pipeline-and-market-analysis\">CAR T-cell platforms<\/a><\/strong> and UniCAR and RevCAR.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine raises USD 255 Million for AI drug discovery Insilico Medicine, a Hong Kong-based global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, closed a USD 255 Million Series C financing. Warburg Pincus led the round with participation from present investors Qiming Venture Partners, Pavilion Capital, Eight Roads [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":12499,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[420,639,5789],"industry":[17225],"therapeutic_areas":[17242,17235,17229,17245],"class_list":["post-12497","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-news","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Insilico raises $255M; Sanofi\u2019s mRNA vaccine; Blackstone&#039;s CAR-T startup<\/title>\n<meta name=\"description\" content=\"Insilico raises $255M; Translate Bio-Sanofi&#039;s mRNA vaccine; Medtronic wins expanded FDA approval; Blackstone, Cellex &amp; Intellia&#039;s CAR-T...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico raises $255M; Sanofi\u2019s mRNA vaccine; Blackstone&#039;s CAR-T startup\" \/>\n<meta property=\"og:description\" content=\"Insilico raises $255M; Translate Bio-Sanofi&#039;s mRNA vaccine; Medtronic wins expanded FDA approval; Blackstone, Cellex &amp; Intellia&#039;s CAR-T...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-24T13:24:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:51:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico raises $255M; Sanofi\u2019s mRNA vaccine; Blackstone's CAR-T startup","description":"Insilico raises $255M; Translate Bio-Sanofi's mRNA vaccine; Medtronic wins expanded FDA approval; Blackstone, Cellex & Intellia's CAR-T...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","og_locale":"en_US","og_type":"article","og_title":"Insilico raises $255M; Sanofi\u2019s mRNA vaccine; Blackstone's CAR-T startup","og_description":"Insilico raises $255M; Translate Bio-Sanofi's mRNA vaccine; Medtronic wins expanded FDA approval; Blackstone, Cellex & Intellia's CAR-T...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-06-24T13:24:23+00:00","article_modified_time":"2022-08-16T04:51:55+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","name":"Insilico raises $255M; Sanofi\u2019s mRNA vaccine; Blackstone's CAR-T startup","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2.jpg","datePublished":"2021-06-24T13:24:23+00:00","dateModified":"2022-08-16T04:51:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Insilico raises $255M; Translate Bio-Sanofi's mRNA vaccine; Medtronic wins expanded FDA approval; Blackstone, Cellex & Intellia's CAR-T...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2.jpg","width":772,"height":482,"caption":"recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/24185354\/recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex-2-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jun 24, 2021","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Jun 24, 2021 6:54 pm","modified":"Updated on Aug 16, 2022 10:21 am"},"featured_img_caption":"recent-pharma-happenings-for-insilico-sanofi-medtronic-blackstone-cellex","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12497"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12497\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12499"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12497"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12497"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}